The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia

相似書籍

• A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib
  由: Ernst, Thomas, et al.
  出版: (2009)
• SGX393 inhibits the CML mutant Bcr-Abl(T315I) and preempts in vitro resistance when combined with nilotinib or dasatinib
  由: O'Hare, Thomas, et al.
  出版: (2008)
• Acute dasatinib exposure commits Bcr-Abl–dependent cells to apoptosis
  由: Snead, Jennifer L., et al.
  出版: (2009)
• Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
  由: Stein, Andrew M, et al.
  出版: (2013)
• Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib
  由: Koldehoff, Michael, et al.
  出版: (2010)